Novavax Initiates Phase 2b/3 Clinical Trial for COVID-19 Vaccine in Children

Strategic Insights -

Novavax has initiated its Phase 2b/3 Hummingbird trial to evaluate the safety, effectiveness, and efficacy of its COVID-19 vaccine (NVX-CoV2373) in children aged six months through 11 years. The trial will assess the vaccine in infants, toddlers, and children, with participants having begun dosing in the six to 11-year-old age group. The trial aims to enroll 3,600 participants across multiple countries, with initial results expected in Q1 2023. The Novavax COVID-19 vaccine is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, using Novavax' recombinant nanoparticle technology and Matrix-M adjuvant to enhance the immune response.

Key Takeaways:

  • Novavax has initiated its Phase 2b/3 Hummingbird trial to evaluate the safety, effectiveness, and efficacy of its COVID-19 vaccine (NVX-CoV2373) in children aged six months through 11 years.
  • The trial will assess the vaccine in infants (six through 23 months of age), toddlers (two through five years), and children (six through 11 years), with participants having begun dosing in the six to 11-year-old age group.
  • The trial aims to enroll 3,600 participants across multiple countries, including the US, Mexico, Colombia, Argentina, Spain, UK, South Africa, Philippines, and Brazil.
  • The trial will assess the vaccine's safety and efficacy in different age groups, with a booster dose given six months after the primary vaccination series.
  • The Novavax COVID-19 vaccine is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, using Novavax' recombinant nanoparticle technology and Matrix-M adjuvant to enhance the immune response.
  • The vaccine is already authorized for use in multiple countries, including the US, EC, and WHO, and is currently under review by multiple regulatory agencies worldwide.
  • Novavax is also evaluating a COVID-seasonal influenza combination vaccine candidate, as well as an Omicron strain-based vaccine and a bivalent Omicron-based/original strain-based vaccine.

Statistics:

  • 3,600 participants will be enrolled in the Phase 2b/3 Hummingbird trial.
  • The trial will be conducted in multiple countries, including the US, Mexico, Colombia, Argentina, Spain, UK, South Africa, Philippines, and Brazil.
  • Initial results from the trial are expected in Q1 2023.
  • The Novavax COVID-19 vaccine has been authorized for use in multiple countries, including the US, EC, and WHO.
  • The vaccine has received positive reviews from regulatory agencies worldwide, with ongoing evaluation for additional indications and populations.

Sources:

  • Novavax, Inc. press release, dated [not specified]
  • Novavax, Inc. Annual Report on Form 10-K for the year ended December 31, 2021
  • Novavax, Inc. Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC)